Impact of TP53 Mutations on Survival in Large B-Cell Lymphoma Patients Treated with CAR-T

A clinical dataset of 195 adult patients with relapsed/refractory large B-cell lymphoma who underwent Next-Generation Sequencing. The data compares survival outcomes for patients with and without TP53 mutations, stratified by treatment with CD19-directed CAR-T cell therapy or non-CAR-T chemotherapy. The dataset was created by Rui Liu and last updated in June 2026.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between CAR-T and chemotherapy cohorts based on the described patient stratification.
• Analyze the association between TP53 mutation types (missense vs. disruptive) and treatment response rates mentioned in the results.
• Investigate the differential impact of mutations in the DNA-binding domain (DBD) versus non-DBD regions on patient outcomes.
• Model the prognostic value of TP53 mutation status in the context of modern immunotherapy treatments.

Strengths

• Includes detailed clinical outcomes for 195 patients, with 75 (38%) identified as having TP53 mutations.
• Compares two distinct treatment modalities: 151 patients received CAR-T therapy and 44 received chemotherapy.
• Reports specific survival metrics, such as a median OS of 12.13 months for TP53-mutated patients on CAR-T versus 2.20 months on chemotherapy.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single retrospective study of 195 patients, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patient records and Next-Generation Sequencing data.

Freshness

Last updated 2026-06-03 06:06:57; freshness should be verified.